Novo Nordisk, the Danish pharmaceutical titan behind Ozempic, revealed today a sweeping global restructuring plan to cut roughly 11% of its total workforce, as rival weight-loss drugs flood the market. Novo Nordisk faces increasing competition from Eli Lilly, the U.S. firm behind Mounjaro, and a new wave of cheaper, compounded alternatives. By cutting around 9,000 positions — more than half of which are based in Denmark — the company anticipates annualized savings of roughly $1.25 billion by the end of 20 ...